Nevertheless, a small study in melanoma designed personalised neoantigen-based peptide vaccines for six patients, which led to the generation of tumour-specific CD4+ and CD8+ T lymphocyte responses and clinical benefit (four out of six patients remaining cancer free at a 25-month follow up) [4]. This evidence concerns the gene CD8A and melanoma.